Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease

This prospective observational study evaluated the possible mechanisms of action of SGLT2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) without overt heart disease. The study was designed to verify whether SGLT2i impact biomarkers of: myocardial stress–NT-proBNP, inflammation–...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2023-08, Vol.37 (8), p.108541-108541, Article 108541
Main Authors: Grubić Rotkvić, Petra, Ćelap, Ivana, Bralić Lang, Valerija, Jug, Juraj, Snagić, Andrea, Huljev Šipoš, Ivana, Cigrovski Berković, Maja
Format: Article
Language:English
Subjects:
Antidiabetics
Asymptomatic
Biomarkers
Blood pressure
Cardiomyopathy
Cardiovascular disease
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic cardiomyopathy
DPP-4 inhibitors
Ejection fraction
Flow velocity
Glucose
Heart Failure
Humans
Hypoglycemic Agents - therapeutic use
Inflammation
Mortality
Observational studies
Oxidative stress
Peptides
Prospective Studies
Pulmonary arteries
SGLT2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This prospective observational study evaluated the possible mechanisms of action of SGLT2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) without overt heart disease. The study was designed to verify whether SGLT2i impact biomarkers of: myocardial stress–NT-proBNP, inflammation–high sensitivity C-reactive protein, oxidative stress –myeloperoxidase, functional and structural echocardiographic parameters, in patients with T2DM on metformin (heart failure stages A and B) who needed treatment intensification with a second antidiabetic agent. The patients were divided in two groups – the ones planned to receive SGLT2i or DPP-4 inhibitor (except saxagliptin). At baseline, and after six months of therapy, 64 patients underwent blood analysis, physical and echocardiography examination. There were no significant differences between the two groups in terms of biomarkers of myocyte and oxidative stress, inflammation and blood pressure. Body mass index, triglycerides, aspartate aminotransferase, uric acid, E/E′, deceleration time and systolic pressure in the pulmonary artery significantly decreased, while stroke volume, indexed stroke volume, high-density lipoprotein, hematocrit and hemoglobin significantly increased in the group on SGLT2i. According to the results, SGLT2i mechanisms of action comprise rapid changes in body composition and metabolic parameters, reduced cardiac load and improvement in diastolic and systolic parameters. •SGLT2 inhibitors reduce the risk of major cardiovascular events.•SGLT2 inhibitors are efficient in primary/secondary prevention of heart failure.•They show pleiotropic effects in patients at risk of developing heart failure.•These effects are: rapid changes in body composition and metabolic parameters.•Furthermore, they reduce cardiac load, improve diastolic and systolic function.
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2023.108541